MTM(SH:688029) Sou Hu Cai Jing·2025-07-23 12:52Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which has a current PE ratio of 25.27, significantly lower than the industry average of 53.52 [1][2] - As of the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also showing a year-on-year increase of 12.18% [1] - The company operates in the minimally invasive medical device sector, with key products including biopsy, hemostasis, closure devices, and various imaging systems [1] Group 2 - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, indicating that Nanwei Medical is undervalued compared to its peers [2] - The total market capitalization of Nanwei Medical is 14.419 billion yuan, with 17 institutions holding a total of 5.4605 million shares valued at 369 million yuan [1][2] - The company's gross profit margin stands at 65.69%, reflecting strong profitability within its operational framework [1]